CA2142863A1 - Compositions homeopathiques pour le traitement des maladies virales et metaboliques - Google Patents

Compositions homeopathiques pour le traitement des maladies virales et metaboliques

Info

Publication number
CA2142863A1
CA2142863A1 CA002142863A CA2142863A CA2142863A1 CA 2142863 A1 CA2142863 A1 CA 2142863A1 CA 002142863 A CA002142863 A CA 002142863A CA 2142863 A CA2142863 A CA 2142863A CA 2142863 A1 CA2142863 A1 CA 2142863A1
Authority
CA
Canada
Prior art keywords
compound
viral
treatment
intracellular
elimination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002142863A
Other languages
English (en)
French (fr)
Inventor
Marie-Christine Etienne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9110899A priority Critical patent/FR2680687A1/fr
Application filed by Individual filed Critical Individual
Priority to CA002142863A priority patent/CA2142863A1/fr
Priority to AU25105/92A priority patent/AU2510592A/en
Priority to DE69223811T priority patent/DE69223811T2/de
Priority to EP92918959A priority patent/EP0655928B1/fr
Priority to PCT/FR1992/000813 priority patent/WO1994004186A1/fr
Publication of CA2142863A1 publication Critical patent/CA2142863A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002142863A 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques Abandoned CA2142863A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR9110899A FR2680687A1 (fr) 1991-08-29 1991-08-29 Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales.
CA002142863A CA2142863A1 (fr) 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques
AU25105/92A AU2510592A (en) 1991-08-29 1992-08-21 Homeopathic compositions for the treatment of viral and metabolic diseases
DE69223811T DE69223811T2 (de) 1991-08-29 1992-08-21 Verwendung eines homöopathisches Erzeugnisses zur Herstellung eines Arzneimittels für die Behandlung von metabolischen Krankheiten
EP92918959A EP0655928B1 (fr) 1991-08-29 1992-08-21 Utilisation d'un produit homéopathique pour la préparation d'un médicament destiné au traitement de maladies métaboliques
PCT/FR1992/000813 WO1994004186A1 (fr) 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9110899A FR2680687A1 (fr) 1991-08-29 1991-08-29 Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales.
CA002142863A CA2142863A1 (fr) 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques
PCT/FR1992/000813 WO1994004186A1 (fr) 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques

Publications (1)

Publication Number Publication Date
CA2142863A1 true CA2142863A1 (fr) 1994-03-03

Family

ID=27169961

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002142863A Abandoned CA2142863A1 (fr) 1991-08-29 1992-08-21 Compositions homeopathiques pour le traitement des maladies virales et metaboliques

Country Status (3)

Country Link
CA (1) CA2142863A1 (enrdf_load_stackoverflow)
FR (1) FR2680687A1 (enrdf_load_stackoverflow)
WO (1) WO1994004186A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713487B1 (fr) * 1993-12-09 1996-02-02 Labo Life Solutions de type homéopathique contenant un acide nucléique utilisables notamment dans la prévention ou le traitement de maladies infectieuses ou de maladies impliquant le dysfonctionnement d'un gène.
GB9426409D0 (en) * 1994-12-30 1995-03-01 Britannia Health Products Ltd A composition for treating endometriosis
US6140305A (en) 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
DE69841593D1 (de) 1997-06-13 2010-05-12 Bio Rad Laboratories Verfahren und Zusammensetzungen für die Diagnose und die Behandlung von Krankheiten, die mit Eisenüberschuss oder Eisenmangel assoziiert sind
EP2568958A1 (en) * 2010-05-14 2013-03-20 Deseret Biologicals, Inc. Formulations of diluted genetic material and methods for making same
US9603898B2 (en) 2011-03-23 2017-03-28 Deseret Biologicals, Inc. Formulations of diluted amino acid segments and methods for making same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624013B2 (fr) * 1987-10-08 1991-07-12 Medibrevex Application comme medicaments utiles pour le traitement allopathique des maladies allergiques de formes galeniques d'oeufs de caille

Also Published As

Publication number Publication date
FR2680687A1 (fr) 1993-03-05
FR2680687B1 (enrdf_load_stackoverflow) 1995-03-24
WO1994004186A1 (fr) 1994-03-03

Similar Documents

Publication Publication Date Title
Prantera et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx
Chan et al. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability
Lund et al. Treatment of acute methylmercury ingestion by hemodialysis with N-acetylcysteine (Mucomyst) infusion and 2, 3-dimercaptopropane sulfonate
JP2007515469A5 (enrdf_load_stackoverflow)
Eder et al. How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions
EP2670405B1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
CA2142863A1 (fr) Compositions homeopathiques pour le traitement des maladies virales et metaboliques
WO2023109747A1 (zh) 2,4-二羟基苯甲酸在治疗铁过载疾病药品中的应用
Mustafi et al. Pulse therapy: opening new vistas in treatment of pemphigus
Kalogirou et al. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus
JP2017506249A (ja) 放射性核種及び金属のキレート剤を送達するための逆ミセルシステムの使用
Stark et al. Dissolution of Cystine Calculi by Pelviocaliceal Irrigation with B-Penicillamine
Epstein et al. Triethylene tetramine dihydrochloride toxicity in primary biliary cirrhosis
US20170119707A1 (en) Homeopathic topical gel for transdermal delivery of colchicine formulations and method of use
Maduri et al. Formulation of colchicine ointment for the treatment of acute gout
El-Shershaby et al. Radiolabeling and cytotoxicity of monoclonal antibody Isatuximab functionalized silver nanoparticles on the growth of multiple myeloma
US20220280451A1 (en) Treatment of copper disorder
EP1056461A1 (en) Method and means for treating glomerulonephritis
US6663850B2 (en) Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
JP2015536330A (ja) トリメチルアミン−ｎ−オキシドのレベルを下げる医薬組成物
Saxena et al. Comparison of piroxicam and acetylsalicylic acid for pain in head and neck cancers: a double-blind study
US20040265299A1 (en) Oral pharmaceutical formulation containing active carbon and use of the same
CN109963559A (zh) 舌下或颊部施用dim以治疗皮肤病
Ly et al. Mercuric oxide poisoning treated with whole-bowel irrigation and chelation therapy
EP0655928A1 (fr) Utilisation d'un produit homéopathique pour la préparation d'un médicament destiné au traitement de maladies métaboliques

Legal Events

Date Code Title Description
FZDE Dead